ADVANCE study shows high frequency of major weight gain in women receiving dolutegravir with TAF
Metabolic syndrome – including obesity – developed significantly more frequently in people who received dolutegravir, tenofovir alafenamide (TAF) and emtricitabine compared to other regimens in the South African ADVANCE study, Michelle Moorhouse reported on Thursday at the 17th European AIDS Conference in Basel, Switzerland. Furthermore, updated follow-up from the study showed that close to 60%… Read More »